Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen
| العنوان: | Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen |
|---|---|
| المؤلفون: | Aaron D. Schimmer, Solaf Kanfar, Dawn Maze, Anna Xu, Jack T Seki, Caroline J McNamara, Tracy Murphy, Xing Liu, Hassan Sibai, Steven M. Chan, Ruiqi Chen, Mark D. Minden, Vikas Gupta, Andre C. Schuh, Karen W.L. Yee, Umberto Falcone, Arjun Datt Law |
| المصدر: | Current Oncology Volume 28 Issue 1 Pages 16-137 Current Oncology, Vol 28, Iss 16, Pp 128-137 (2021) |
| بيانات النشر: | MDPI, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Adult, Asparaginase, medicine.medical_specialty, philadelphia-positive acute leukemia, medicine.drug_class, medicine.medical_treatment, venous thromboembolism, Low molecular weight heparin, acute lymphoblastic leukemia, 030204 cardiovascular system & hematology, Gastroenterology, Article, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Maintenance therapy, Internal medicine, medicine, Humans, cardiovascular diseases, treatment-related thrombosis, Child, RC254-282, Retrospective Studies, Chemotherapy, business.industry, Incidence (epidemiology), Cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Anticoagulants, Thrombosis, cancer-related thrombosis, Heparin, Low-Molecular-Weight, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, Regimen, chemistry, 030220 oncology & carcinogenesis, business, Complication |
| الوصف: | Background: venous thromboembolism (VTE) is a well-known complication in adults with acute lymphoblastic leukemia (ALL), especially in patients treated with asparaginase (ASNase)-including regiments. However, VTE risk in adult Philadelphia-positive ALL (Ph+ve ALL) patients treated with non-hyperCVAD chemotherapy is unclear. In this study, we examined VTE incidence in adult Ph+ve ALL patients treated with imatinib plus a pediatric-inspired asparaginase (ASNase)-free regimen modified from the Dana Farber Cancer Institute (DFCI) ALL protocol. Methods: a single centre retrospective review of Ph+ve ALL patients treated at Princess Margaret Cancer Center (PMCC) from 2008&ndash 2019 with imatinib plus modified DFCI protocol was conducted. Results: of the 123 patients included, 30 (24.3%) had at least 1 radiology confirmed VTE event from diagnosis to the end of maintenance therapy. 86.7% (26/30) of the VTE events occurred during active treatment. Of all VTE events, the majority (53.3%) were DVT and/or PE while another significant portion were catheter-related (40.0%). Major bleeding was observed in 1 patient on VTE treatment with low molecular weight heparin (LMWH). Conclusion: a high VTE incidence (24.3%) was observed in adults Ph+ve ALL patients treated with imatinib plus an ASNase-free modified DFCI pediatric ALL protocol, suggesting prophylactic anticoagulation should be considered for all adult Ph+ve ALL patients including those treated with ASNase-free regimens. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1718-7729 1198-0052 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::515a92a612754448c6089b19b76a7583 http://europepmc.org/articles/PMC7816186 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....515a92a612754448c6089b19b76a7583 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17187729 11980052 |
|---|